ArticlePediatric investigation2026
Bortezomib-based chemotherapy in Chinese pediatric patients with relapsed/refractory acute lymphoblastic leukemia: A single-center retrospective study.
Article in Pediatric investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Relapsed/refractory acute lymphoblastic leukemia (R/R ALL) remains a major challenge in pediatric hematologic malignancies, with poor outcomes following standard salvage therapy. Real-world data regarding the use of bortezomib-based regimens in Chinese children are limited. Objective: To evaluate the effectiveness and safety of bortezomib-based chemotherapy in Chinese pediatric patients with R/R ALL. Methods: We retrospectively reviewed 12 pediatric patients with R/R ALL who received bortezomib-based chemotherapy at our center between January 2019 and January 2026. Clinical characteristics, responses, survival, and adverse events were evaluated. Complete remission (CR), CR with incomplete recovery (CRi), persistent disease (PD), and minimal residual disease (MRD) were assessed per standard criteria. Survival probabilities were estimated using the Kaplan-Meier analysis. Results: Nine patients had B-cell ALL (B-ALL) and three had T-cell ALL (T-ALL). Among those with B-ALL, the CR/CRi rate was 88.9% (8/9), and 62.5% (5/8) of responders bridged to hematopoietic stem cell transplantation (HSCT). Notably, five of eight responders with B-ALL achieved MRD <0.01%, including all three refractory patients. In contrast, none of the three patients with T-ALL achieved remission; all experienced PD, with a median survival of 3 months. The 3-year overall survival and event-free survival rates for the entire cohort were 48.6% (95% confidence interval [CI], 19.2%-73.0%) and 36.4% (95% CI, 5.8%-69.8%), respectively. Treatment-related toxicities were manageable, with the most common being hematologic suppression and infections. Interpretation: Bortezomib-based chemotherapy showed promising salvage activity in pediatric patients with R/R B-ALL, enabling remission and HSCT bridging. However, its activity against T-ALL appears limited in this small cohort, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.